Literature DB >> 11668013

Effects of naltrexone on the intake of ethanol and flavored solutions in rats.

F L Goodwin1, M Campisi, I Babinska, Z Amit.   

Abstract

It has been suggested that the endogenous opioid system may mediate the intake of preferred fluids, perhaps through an attenuation of reinforcement properties causing a subsequent shift in palatability. The purpose of the present study was to investigate the effects of the nonspecific opiate antagonist naltrexone on the intake of 10% ethanol, 0.1% saccharin, 0.0006% quinine, 0.4% saccharin + 10% ethanol, and 0.4% saccharin + 0.04% quinine solutions. Fluid intake was measured in male Long-Evans and Wistar rats under 24-h continuous and 30-min limited-fluid-access drinking paradigms. All rats received injections of naltrexone hydrochloride (10 mg/kg, i.p.) for 5 days after baseline intake measures and were monitored for a further 5 days (after-treatment phase). Results indicated that naltrexone did not affect intake of any solution when fluids were available over 24 h. However, under limited-access conditions, naltrexone caused a decrease in the intake of all fluids except quinine in both rat strains. On the basis of these findings, it is possible that the effects of this dose of naltrexone were not due to any true conditioning effect on the reinforcement properties of ethanol, but perhaps to some nonspecific effect of the drug, such as an alteration in palatability or an attenuation of locomotor activity. As well, due to the inconsistent results in fluid intake across drinking paradigms, the present findings do not provide evidence for an effective role for opiate mediation in ethanol intake as well as any ethanol-sweet fluid intake interactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668013     DOI: 10.1016/s0741-8329(01)00163-x

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  8 in total

1.  Low-dose prazosin alone and in combination with propranolol or naltrexone: effects on ethanol and sucrose seeking and self-administration in the P rat.

Authors:  Terril L Verplaetse; Cristine L Czachowski
Journal:  Psychopharmacology (Berl)       Date:  2015-03-07       Impact factor: 4.530

2.  The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models.

Authors:  Catherine F Moore; Omar A Protzuk; Bankole A Johnson; Wendy J Lynch
Journal:  Pharmacol Biochem Behav       Date:  2013-11-16       Impact factor: 3.533

3.  Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice.

Authors:  Arthur Tomie; Idu Azogu; Lei Yu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-03-13       Impact factor: 5.067

4.  The mGluR2 Positive Allosteric Modulator, AZD8529, and Cue-Induced Relapse to Alcohol Seeking in Rats.

Authors:  Eric Augier; Russell S Dulman; Caroline Rauffenbart; Gaëlle Augier; Alan J Cross; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2016-06-24       Impact factor: 7.853

5.  Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats.

Authors:  Dong Ji; Nicholas W Gilpin; Heather N Richardson; Catherine L Rivier; George F Koob
Journal:  Behav Pharmacol       Date:  2008-02       Impact factor: 2.293

Review 6.  Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal.

Authors:  Tamzin L Ripley; David N Stephens
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice.

Authors:  N K Kamdar; S A Miller; Y M Syed; R Bhayana; T Gupta; J S Rhodes
Journal:  Psychopharmacology (Berl)       Date:  2007-02-02       Impact factor: 4.415

8.  Evaluating the Impact of Naltrexone on the Rat Gambling Task to Test Its Predictive Validity for Gambling Disorder.

Authors:  Patricia Di Ciano; Bernard Le Foll
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.